Summary
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.
Peptide Cancer Vaccine Segment by Company
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Peptide Cancer Vaccine Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Peptide Cancer Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
- Market Overview
- Product Definition
- Global Peptide Cancer Vaccine Market Size, 2020 VS 2024 VS 2031
- Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2020-2031)
- Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2020-2031)
- Global Peptide Cancer Vaccine Market Average Price (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- Global Peptide Cancer Vaccine Market Dynamics
- Peptide Cancer Vaccine Industry Trends
- Peptide Cancer Vaccine Industry Drivers
- Peptide Cancer Vaccine Industry Opportunities and Challenges
- Peptide Cancer Vaccine Industry Restraints
- Peptide Cancer Vaccine Market by Manufacturers
- Global Peptide Cancer Vaccine Revenue by Manufacturers (2020-2025)
- Global Peptide Cancer Vaccine Sales by Manufacturers (2020-2025)
- Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2020-2025)
- Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
- Global Peptide Cancer Vaccine Manufacturers Establishment Date
- Market Competitive Analysis
- Global Peptide Cancer Vaccine Market CR5 and HHI
- Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2024
- 2024 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
- Peptide Cancer Vaccine Market by Type
- Peptide Cancer Vaccine Type Introduction
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Global Peptide Cancer Vaccine Sales by Type
- Global Peptide Cancer Vaccine Sales by Type (2020 VS 2024 VS 2031)
- Global Peptide Cancer Vaccine Sales by Type (2020-2031)
- Global Peptide Cancer Vaccine Sales Market Share by Type (2020-2031)
- Global Peptide Cancer Vaccine Revenue by Type
- Global Peptide Cancer Vaccine Revenue by Type (2020 VS 2024 VS 2031)
- Global Peptide Cancer Vaccine Revenue by Type (2020-2031)
- Global Peptide Cancer Vaccine Revenue Market Share by Type (2020-2031)
- Peptide Cancer Vaccine Type Introduction
- Peptide Cancer Vaccine Market by Application
- Peptide Cancer Vaccine Application Introduction
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- Global Peptide Cancer Vaccine Sales by Application
- Global Peptide Cancer Vaccine Sales by Application (2020 VS 2024 VS 2031)
- Global Peptide Cancer Vaccine Sales by Application (2020-2031)
- Global Peptide Cancer Vaccine Sales Market Share by Application (2020-2031)
- Global Peptide Cancer Vaccine Revenue by Application
- Global Peptide Cancer Vaccine Revenue by Application (2020 VS 2024 VS 2031)
- Global Peptide Cancer Vaccine Revenue by Application (2020-2031)
- Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2031)
- Peptide Cancer Vaccine Application Introduction
- Global Peptide Cancer Vaccine Sales by Region
- Global Peptide Cancer Vaccine Sales by Region: 2020 VS 2024 VS 2031
- Global Peptide Cancer Vaccine Sales by Region (2020-2031)
- Global Peptide Cancer Vaccine Sales by Region (2020-2025)
- Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030)
- North America
- North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- North America Peptide Cancer Vaccine Sales by Country (2020-2031)
- U.S.
- Canada
- Mexico
- Europe
- Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Europe Peptide Cancer Vaccine Sales by Country (2020-2031)
- Germany
- France
- U.K.
- Italy
- Netherlands
- Asia Pacific
- Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Asia Pacific Peptide Cancer Vaccine Sales by Country (2020-2031)
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- South America, Middle East and Africa
- South America, Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2020-2031)
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- Argentina
- UAE
- Egypt
- Chile
- Global Peptide Cancer Vaccine Revenue by Region
- Global Peptide Cancer Vaccine Revenue by Region
- Global Peptide Cancer Vaccine Revenue by Region: 2020 VS 2024 VS 2031
- Global Peptide Cancer Vaccine Revenue by Region (2020-2025)
- Global Peptide Cancer Vaccine Revenue by Region (2026-2031)
- Global Peptide Cancer Vaccine Revenue Market Share by Region (2020-2031)
- North America
- North America Peptide Cancer Vaccine Revenue (2020-2031)
- North America Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- Europe
- Europe Peptide Cancer Vaccine Revenue (2020-2031)
- Europe Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- Asia-Pacific
- Asia-Pacific Peptide Cancer Vaccine Revenue (2020-2031)
- Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa
- South America, Middle East and Africa Peptide Cancer Vaccine Revenue (2020-2031)
- South America, Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031
- Global Peptide Cancer Vaccine Revenue by Region
- Company Profiles
- Boston Biomedical
- Boston Biomedical Comapny Information
- Boston Biomedical Business Overview
- Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Boston Biomedical Peptide Cancer Vaccine Product Portfolio
- Boston Biomedical Recent Developments
- Ultimovacs
- Ultimovacs Comapny Information
- Ultimovacs Business Overview
- Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Ultimovacs Peptide Cancer Vaccine Product Portfolio
- Ultimovacs Recent Developments
- BrightPath Biotherapeutics
- BrightPath Biotherapeutics Comapny Information
- BrightPath Biotherapeutics Business Overview
- BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
- BrightPath Biotherapeutics Recent Developments
- TapImmune
- TapImmune Comapny Information
- TapImmune Business Overview
- TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- TapImmune Peptide Cancer Vaccine Product Portfolio
- TapImmune Recent Developments
- Immatics
- Immatics Comapny Information
- Immatics Business Overview
- Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Immatics Peptide Cancer Vaccine Product Portfolio
- Immatics Recent Developments
- Sellas
- Sellas Comapny Information
- Sellas Business Overview
- Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Sellas Peptide Cancer Vaccine Product Portfolio
- Sellas Recent Developments
- Imugene
- Imugene Comapny Information
- Imugene Business Overview
- Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Imugene Peptide Cancer Vaccine Product Portfolio
- Imugene Recent Developments
- VAXON Biotech
- VAXON Biotech Comapny Information
- VAXON Biotech Business Overview
- VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- VAXON Biotech Peptide Cancer Vaccine Product Portfolio
- VAXON Biotech Recent Developments
- Generex Biotechnology
- Generex Biotechnology Comapny Information
- Generex Biotechnology Business Overview
- Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- Generex Biotechnology Recent Developments
- ISA Pharmaceuticals
- ISA Pharmaceuticals Comapny Information
- ISA Pharmaceuticals Business Overview
- ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- ISA Pharmaceuticals Recent Developments
- OncoTherapy Science
- OncoTherapy Science Comapny Information
- OncoTherapy Science Business Overview
- OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
- OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- OncoTherapy Science Recent Developments
- Boston Biomedical
- Value Chain and Sales Channels Analysis
- Peptide Cancer Vaccine Value Chain Analysis
- Peptide Cancer Vaccine Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- Peptide Cancer Vaccine Production Mode & Process
- Peptide Cancer Vaccine Sales Channels Analysis
- Direct Comparison with Distribution Share
- Peptide Cancer Vaccine Distributors
- Peptide Cancer Vaccine Customers
- Peptide Cancer Vaccine Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :Peptide Cancer Vaccine Industry Trends |
Table 2 | :Peptide Cancer Vaccine Industry Drivers |
Table 3 | :Peptide Cancer Vaccine Industry Opportunities and Challenges |
Table 4 | :Peptide Cancer Vaccine Industry Restraints |
Table 5 | :Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2020-2025) |
Table 6 | :Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2020-2025) |
Table 7 | :Global Peptide Cancer Vaccine Sales by Manufacturers (K Doses) & (2020-2025) |
Table 8 | :Global Peptide Cancer Vaccine Sales Market Share by Manufacturers |
Table 9 | :Global Peptide Cancer Vaccine Average Sales Price (USD/Dose) of Manufacturers (2020-2025) |
Table 10 | :Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025 |
Table 11 | :Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters |
Table 12 | :Global Peptide Cancer Vaccine Manufacturers, Product Type & Application |
Table 13 | :Global Peptide Cancer Vaccine Manufacturers Establishment Date |
Table 14 | :Global Manufacturers Market Concentration Ratio (CR5 and HHI) |
Table 15 | :Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2024) |
Table 16 | :Major Manufacturers of ITK-1 |
Table 17 | :Major Manufacturers of GRN-1201 |
Table 18 | :Major Manufacturers of TPIV200 |
Table 19 | :Major Manufacturers of TPIV110 |
Table 20 | :Major Manufacturers of UV1 |
Table 21 | :Major Manufacturers of Galinpepimut-S |
Table 22 | :Major Manufacturers of TARP 27-35 |
Table 23 | :Major Manufacturers of HER-Vaxx |
Table 24 | :Major Manufacturers of Vx-001 |
Table 25 | :Major Manufacturers of Others |
Table 26 | :Global Peptide Cancer Vaccine Sales by Type 2020 VS 2024 VS 2031 (K Doses) |
Table 27 | :Global Peptide Cancer Vaccine Sales by Type (2020-2025) & (K Doses) |
Table 28 | :Global Peptide Cancer Vaccine Sales by Type (2026-2031) & (K Doses) |
Table 29 | :Global Peptide Cancer Vaccine Sales Market Share by Type (2020-2025) |
Table 30 | :Global Peptide Cancer Vaccine Sales Market Share by Type (2026-2031) |
Table 31 | :Global Peptide Cancer Vaccine Revenue by Type 2020 VS 2024 VS 2031 (K Doses) |
Table 32 | :Global Peptide Cancer Vaccine Revenue by Type (2020-2025) & (K Doses) |
Table 33 | :Global Peptide Cancer Vaccine Revenue by Type (2026-2031) & (K Doses) |
Table 34 | :Global Peptide Cancer Vaccine Revenue Market Share by Type (2020-2025) |
Table 35 | :Global Peptide Cancer Vaccine Revenue Market Share by Type (2026-2031) |
Table 36 | :Major Manufacturers of Breast Cancer |
Table 37 | :Major Manufacturers of Lung Cancer |
Table 38 | :Major Manufacturers of Melanoma |
Table 39 | :Major Manufacturers of Prostate Cancer |
Table 40 | :Major Manufacturers of Others |
Table 41 | :Global Peptide Cancer Vaccine Sales by Application 2020 VS 2024 VS 2031 (K Doses) |
Table 42 | :Global Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Doses) |
Table 43 | :Global Peptide Cancer Vaccine Sales by Application (2026-2031) & (K Doses) |
Table 44 | :Global Peptide Cancer Vaccine Sales Market Share by Application (2020-2025) |
Table 45 | :Global Peptide Cancer Vaccine Sales Market Share by Application (2026-2031) |
Table 46 | :Global Peptide Cancer Vaccine Revenue by Application 2020 VS 2024 VS 2031 (K Doses) |
Table 47 | :Global Peptide Cancer Vaccine Revenue by Application (2020-2025) & (K Doses) |
Table 48 | :Global Peptide Cancer Vaccine Revenue by Application (2026-2031) & (K Doses) |
Table 49 | :Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2025) |
Table 50 | :Global Peptide Cancer Vaccine Revenue Market Share by Application (2026-2031) |
Table 51 | :Global Peptide Cancer Vaccine Sales by Region: 2020 VS 2024 VS 2031 (K Doses) |
Table 52 | :Global Peptide Cancer Vaccine Sales by Region (2020-2025) & (K Doses) |
Table 53 | :Global Peptide Cancer Vaccine Sales Market Share by Region (2020-2025) |
Table 54 | :Global Peptide Cancer Vaccine Sales Forecasted by Region (2026-2031) & (K Doses) |
Table 55 | :Global Peptide Cancer Vaccine Sales Forecasted Market Share by Region (2026-2031) |
Table 56 | :North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Doses) |
Table 57 | :North America Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Doses) |
Table 58 | :North America Peptide Cancer Vaccine Sales by Country (2026-2031) & (K Doses) |
Table 59 | :Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Doses) |
Table 60 | :Europe Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Doses) |
Table 61 | :Europe Peptide Cancer Vaccine Sales by Country (2026-2031) & (K Doses) |
Table 62 | :Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Doses) |
Table 63 | :Asia Pacific Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Doses) |
Table 64 | :Asia Pacific Peptide Cancer Vaccine Sales by Country (2026-2031) & (K Doses) |
Table 65 | :South America, Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Doses) |
Table 66 | :South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Doses) |
Table 67 | :South America, Middle East and Africa Peptide Cancer Vaccine Sales by Country (2026-2031) & (K Doses) |
Table 68 | :Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 69 | :Global Peptide Cancer Vaccine Revenue by Region (2020-2025) & (US$ Million) |
Table 70 | :Global Peptide Cancer Vaccine Revenue by Region (2026-2031) & (US$ Million) |
Table 71 | :Global Peptide Cancer Vaccine Revenue Market Share by Region (2020-2025) |
Table 72 | :Global Peptide Cancer Vaccine Revenue Market Share by Region (2026-2031) |
Table 73 | :Boston Biomedical Company Information |
Table 74 | :Boston Biomedical Business Overview |
Table 75 | :Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 76 | :Boston Biomedical Peptide Cancer Vaccine Product Portfolio |
Table 77 | :Boston Biomedical Recent Development |
Table 78 | :Ultimovacs Company Information |
Table 79 | :Ultimovacs Business Overview |
Table 80 | :Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 81 | :Ultimovacs Peptide Cancer Vaccine Product Portfolio |
Table 82 | :Ultimovacs Recent Development |
Table 83 | :BrightPath Biotherapeutics Company Information |
Table 84 | :BrightPath Biotherapeutics Business Overview |
Table 85 | :BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 86 | :BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio |
Table 87 | :BrightPath Biotherapeutics Recent Development |
Table 88 | :TapImmune Company Information |
Table 89 | :TapImmune Business Overview |
Table 90 | :TapImmune Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 91 | :TapImmune Peptide Cancer Vaccine Product Portfolio |
Table 92 | :TapImmune Recent Development |
Table 93 | :Immatics Company Information |
Table 94 | :Immatics Business Overview |
Table 95 | :Immatics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 96 | :Immatics Peptide Cancer Vaccine Product Portfolio |
Table 97 | :Immatics Recent Development |
Table 98 | :Sellas Company Information |
Table 99 | :Sellas Business Overview |
Table 100 | :Sellas Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 101 | :Sellas Peptide Cancer Vaccine Product Portfolio |
Table 102 | :Sellas Recent Development |
Table 103 | :Imugene Company Information |
Table 104 | :Imugene Business Overview |
Table 105 | :Imugene Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 106 | :Imugene Peptide Cancer Vaccine Product Portfolio |
Table 107 | :Imugene Recent Development |
Table 108 | :VAXON Biotech Company Information |
Table 109 | :VAXON Biotech Business Overview |
Table 110 | :VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 111 | :VAXON Biotech Peptide Cancer Vaccine Product Portfolio |
Table 112 | :VAXON Biotech Recent Development |
Table 113 | :Generex Biotechnology Company Information |
Table 114 | :Generex Biotechnology Business Overview |
Table 115 | :Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 116 | :Generex Biotechnology Peptide Cancer Vaccine Product Portfolio |
Table 117 | :Generex Biotechnology Recent Development |
Table 118 | :ISA Pharmaceuticals Company Information |
Table 119 | :ISA Pharmaceuticals Business Overview |
Table 120 | :ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 121 | :ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio |
Table 122 | :ISA Pharmaceuticals Recent Development |
Table 123 | :OncoTherapy Science Company Information |
Table 124 | :OncoTherapy Science Business Overview |
Table 125 | :OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 126 | :OncoTherapy Science Peptide Cancer Vaccine Product Portfolio |
Table 127 | :OncoTherapy Science Recent Development |
Table 128 | :Key Raw Materials |
Table 129 | :Raw Materials Key Suppliers |
Table 130 | :Peptide Cancer Vaccine Distributors List |
Table 131 | :Peptide Cancer Vaccine Customers List |
Table 132 | :Research Programs/Design for This Report |
Table 133 | :Authors List of This Report |
Table 134 | :Secondary Sources |
Table 135 | :Primary Sources |
List of Figures
Figure 1 | :Peptide Cancer Vaccine Product Image |
Figure 2 | :Global Peptide Cancer Vaccine Market Size (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Peptide Cancer Vaccine Market Size (2020-2031) & (US$ Million) |
Figure 4 | :Global Peptide Cancer Vaccine Sales (2020-2031) & (K Doses) |
Figure 5 | :Global Peptide Cancer Vaccine Average Price (USD/Dose) & (2020-2031) |
Figure 6 | :Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023 |
Figure 7 | :Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 |
Figure 8 | :ITK-1 Image |
Figure 9 | :GRN-1201 Image |
Figure 10 | :TPIV200 Image |
Figure 11 | :TPIV110 Image |
Figure 12 | :UV1 Image |
Figure 13 | :Galinpepimut-S Image |
Figure 14 | :TARP 27-35 Image |
Figure 15 | :HER-Vaxx Image |
Figure 16 | :Vx-001 Image |
Figure 17 | :Others Image |
Figure 18 | :Global Peptide Cancer Vaccine Sales by Type (2020 VS 2024 VS 2031) & (K Doses) |
Figure 19 | :Global Peptide Cancer Vaccine Sales Market Share 2020 VS 2024 VS 2031 |
Figure 20 | :Global Peptide Cancer Vaccine Sales Market Share by Type (2020-2031) |
Figure 21 | :Global Peptide Cancer Vaccine Revenue by Type (2020 VS 2024 VS 2031) & (K Doses) |
Figure 22 | :Global Peptide Cancer Vaccine Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 23 | :Global Peptide Cancer Vaccine Revenue Market Share by Type (2020-2031) |
Figure 24 | :Breast Cancer Image |
Figure 25 | :Lung Cancer Image |
Figure 26 | :Melanoma Image |
Figure 27 | :Prostate Cancer Image |
Figure 28 | :Others Image |
Figure 29 | :Global Peptide Cancer Vaccine Sales by Application (2020 VS 2024 VS 2031) & (K Doses) |
Figure 30 | :Global Peptide Cancer Vaccine Sales Market Share 2020 VS 2024 VS 2031 |
Figure 31 | :Global Peptide Cancer Vaccine Sales Market Share by Application (2020-2031) |
Figure 32 | :Global Peptide Cancer Vaccine Revenue by Application (2020 VS 2024 VS 2031) & (K Doses) |
Figure 33 | :Global Peptide Cancer Vaccine Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 34 | :Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2031) |
Figure 35 | :North America Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 36 | :North America Peptide Cancer Vaccine Sales Market Share by Country (2020-2031) |
Figure 37 | :U.S. Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 38 | :Canada Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 39 | :Mexico Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 40 | :Europe Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 41 | :Europe Peptide Cancer Vaccine Sales Market Share by Country (2020-2031) |
Figure 42 | :Germany Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 43 | :France Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 44 | :U.K. Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 45 | :Italy Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 46 | :Netherlands Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 47 | :Asia Pacific Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 48 | :Asia Pacific Peptide Cancer Vaccine Sales Market Share by Country (2020-2031) |
Figure 49 | :China Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 50 | :Japan Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 51 | :South Korea Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 52 | :Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 53 | :India Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 54 | :Australia Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 55 | :South America, Middle East and Africa Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 56 | :South America, Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2020-2031) |
Figure 57 | :Brazil Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 58 | :South Africa Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 59 | :Saudi Arabia Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 60 | :Turkey Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 61 | :Argentina Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 62 | :UAE Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 63 | :Egypt Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 64 | :Chile Peptide Cancer Vaccine Sales and Growth Rate (2020-2031) & (K Doses) |
Figure 65 | :Global Peptide Cancer Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 66 | :Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2023 Versus 2030 |
Figure 67 | :North America Peptide Cancer Vaccine Revenue (2020-2031) & (US$ Million) |
Figure 68 | :North America Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 69 | :Europe Peptide Cancer Vaccine Revenue (2020-2031) & (US$ Million) |
Figure 70 | :Europe Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 71 | :Asia-Pacific Peptide Cancer Vaccine Revenue (2020-2031) & (US$ Million) |
Figure 72 | :Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 73 | :South America, Middle East and Africa Peptide Cancer Vaccine Revenue (2020-2031) & (US$ Million) |
Figure 74 | :South America, Middle East and Africa Peptide Cancer Vaccine Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 75 | :Peptide Cancer Vaccine Value Chain |
Figure 76 | :Manufacturing Cost Structure |
Figure 77 | :Peptide Cancer Vaccine Production Mode & Process |
Figure 78 | :Direct Comparison with Distribution Share |
Figure 79 | :Distributors Profiles |
Figure 80 | :Years Considered |
Figure 81 | :Research Process |
Figure 82 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Pages: 199
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.